2013 Archived Content
Circulating Tumor Cells
Future of Cancer Management
Day 1 | Day 2 | Day 3
Friday, February 15
8:00 am Morning Coffee
8:30 Chairperson's Remarks
Lynn Sorbara, Ph.D., Program Director, NIH/NCI/Division of Cancer Prevention, Cancer Biomarker Research Group
8:35 Application of iCTC Detection and Culture in Personalized Cancer Management
Wen-Tien Chen, Ph.D., Research Professor, Gynecologic Oncology, Stony Brook University Medical Center
Isolation and culture of invasive CTCs (iCTCs) by their interaction with cell adhesion matrix (CAM), rather than cell surface antibodies or physical properties, results in capture of functional metastasis-initiating tumor cells with greater sensitivity. This makes possible early detection of tumor aggressivity, treatment response monitoring and drug sensitivity testing, as well as development of mouse and cell line metastasis models.
9:05 Microfluidic Sorting of Blood Cells for Cellular and Molecular Analysis
David A. Lawrence, Ph.D., Chief, Laboratory of Immunology, Wadsworth Center, NYSDOH
A microfluidic, size-based sorting array (3 cm x 1 cm) has been adapted to accommodate a 1 cm2 grating-coupled surface plasmon resonance (GCSPR) chip spotted to capture hundreds of different soluble analytes or cells.Cells can be quantified by GCSPR and plasma or cell-released analytes by coupled fluorescence for a more systemic diagnostic and prognostic analysis.
9:35 Cancer Sample Preparation with Micromachined Magnetic Sifter and Nanoparticles
Shan X. Wang, Ph.D., Professor of Materials Science & Engineering, jointly of Electrical Engineering, and by courtesy of Radiology (Stanford School of Medicine), Director, Stanford Center for Magnetic Nanotechnology
Rare cell enrichment and post analysis of peripheral blood samples from cancer patients hold great promises for prognosis and personalized therapy. We present a micromachined magnetic sifter device which can efficiently capture circulating tumor cells at a high flow rate of 10 mL/hour. The device is also promising for multiplex sorting of rare cells with multiple surface biomarkers.
10:05 Nonfluorescent Microfilter with Uniform Pore Distribution to Isolate and Analyze CTCsCha-Mei Tang, Sc.D., President & CEO, Creatv MicroTech, Inc.
10:35 Coffee Break
10:55 Chairperson's Remarks
Steven A. Soper, Ph.D., Professor, Biomedical Engineering; Professor, Chemistry; Director, CBMM; Pryor Emeritus Professor (LSU), University of North Carolina, Chapel Hill
11:00 Photoacoustic Detection and Capture of CTCs
Martin E. Sanders, M.D., Executive Chairman, Viator Technologies, Inc.
Photoacoustic flowmetry is a method of detecting and capturing circulating tumor cells. It is similar to fluorescence flow cytometers, except that the signal is a laser induced ultrasonic signal in cells of interest, providing a robust means for finding single CTCs among large numbers of normal cells. Once detected, the cells are captured for molecular analyses.
11:30 The Fluid Phase of Solid Tumors: How Does Cancer Spread?
Peter Kuhn, Ph.D., Associate Processor, Cell Biology, The Scripps Research Institute
The fluid phase of solid tumors is a clinical tool in personalized cancer care and an emerging research tool in basic science cancer discoveries. Utilizing the HD-CTC assay we are undertaking a series of clinical studies investigating the metastatic pathways in cancer patients. We are now coupling the experimental data with a theoretical framework for a more complete description of the disease progression. The fluid phase of solid tumors is a critical third microenvironment in the development and progression of carcinomas. Cells originating from primary or secondary sites travel through the blood circulatory system to either get cleared out or initiate new tumor growth. Translational research efforts are attempting to identify the various subtypes of circulating tumor cells (CTCs), their origins, their destinations and their impact on the disease. Understanding and characterizing CTCs is a first step towards utilizing them as both biopsy material and directly as a biomarker. It requires approaches of subtyping CTCs at the single cell level using molecular and cellular approaches.
Results will be presented that describe technical developments and validation, clinical validation and clinical utility of the HD-CTC Technology.
12:00 pm Utilization of Dielectrophoresis for Antigen Independent Circulating Tumor Cell (CTC) Capture Allows for Detection of Heterogeneous Tumor Cell Populations
Andrew Poklepovic, M.D., Assistant Professor, Internal Medicine, Virginia Commonwealth University
One major criticism of antibody mediated capture systems is variable expression patterns within the tumor cell population. Identifying specific markers such as EpCAM excludes cells that have low or no expression and developing a panel of alternate antibodies is time consuming and does not avoid excluding unknown phenotypes. The ApoStream(Tm) antigen independent, dielectrophoresis based CTC enrichment device bypasses antigen expression, and allows for capture of a heterogeneous population of viable tumor cells. This technology enables investigators to analyze various populations of tumor cells and has already demonstrated clinical applicability in a wide variety of cancers, including those not suitable to EpCAM based enrichment.
12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own
1:50 PANEL DISCUSSION
How do we go from prognostication to measuring drug response and will clinical applications require live cells, plasma DNA, RNA or protein-based measurements?
Moderator: Moderator to be Announced
Panelists: Daniel Hayes, M.D., Professor, Internal Medicine, University of Michigan, Ann Arbor
Luis Diaz, M.D., Associate Professor of Oncology, Director of Translational Medicine, Ludwig Center at Johns Hopkins, Kimmel Cancer Center at Johns Hopkins
Lyndsay N. Harris, M.D., Case Comprehensive Cancer Center, Case Western Reserve
3:20 Close of Conference
Day 1 | Day 2 | Day 3